Home › Research › Lewy body dementia
TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A
Brown AL, Wilkins OG, Keuss MJ, Kargbo-Hill SE, Zanovello M, Lee WC, Bampton A, Lee FCY et al.. Nature, 2022-02-23
Topic: Brain proteins, microglia and lab models
Variants of UNC13A, a critical gene for synapse function, increase the risk of amyotrophic lateral sclerosis and frontotemporal dementia 1-3 , two related neurodegenerative diseases defined by mislocalization of the RNA-binding protein TDP-43 4,5 . Here we show that TDP-43 depletion induces robust inclusion of a cryptic exon in UNC13A, resulting in nonsense-mediated decay and loss of UNC13A protein. Two common intronic UNC13A polymorphisms strongly associated with amyotrophic lateral sclerosis and frontotemporal dementia risk overlap with TDP-43 binding sites. These polymorphisms potentiate cryptic exon inclusion, both in cultured cells and in brains and spinal cords from patients with these conditions. Our findings, which demonstrate a genetic link between loss of nuclear TDP-43 function and disease, reveal the mechanism by which UNC13A variants exacerbate the effects of decreased TDP-43 function. They further provide a promising therapeutic target for TDP-43 proteinopathies.
Key findings
- Two common intronic UNC13A polymorphisms strongly associated with amyotrophic lateral sclerosis and frontotemporal dementia risk overlap with TDP-43 binding sites.
- Our findings, which demonstrate a genetic link between loss of nuclear TDP-43 function and disease, reveal the mechanism by which UNC13A variants exacerbate the effects of decreased TDP-43 function.
Why it matters
TDP-43 depletion causes a cryptic exon to be included in UNC13A, leading to loss of UNC13A protein, and common risk variants overlap with TDP-43 binding sites and worsen this. The authors call this a promising therapeutic target, but no treatment has been tested.
Study details
- Evidence strengthLow
Limitations
This is a laboratory molecular-biology study of gene splicing mechanisms; it does not itself test or demonstrate this mechanism in patients, so its clinical relevance depends on future work.
How this study scored 64/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature) |
| Journal's citation record | 4 / 4 | Nature: journal h-index 1,841 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 531 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 88.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 6 / 6 | Cited 47.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 24 other studies in this library |
| Still being cited | 4 / 4 | Cited 369 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Pietro Fratta: h-index 22 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 73 institution(s) in 9 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35197628) |
| Free to read | 2 / 2 | Free to read |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Brown, A. L., Wilkins, O. G., Keuss, M. J., Kargbo-Hill, S. E., Zanovello, M., Lee, W. C., et al. (2022). TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. https://doi.org/10.1038/s41586-022-04436-3
Vancouver
Brown AL, Wilkins OG, Keuss MJ, Kargbo-Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022. doi:10.1038/s41586-022-04436-3. PMID: 35197628.
BibTeX
@article{brown2022-35197628,
author = {Brown, A. L. and Wilkins, O. G. and Keuss, M. J. and Kargbo-Hill, S. E. and Zanovello, M. and Lee, W. C. and Bampton, A. and Lee, F. C. Y. and others},
title = {{TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A}},
journal = {Nature},
year = {2022},
doi = {10.1038/s41586-022-04436-3},
pmid = {35197628},
url = {https://doi.org/10.1038/s41586-022-04436-3}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
24 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.